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Ulcerative Colitis (UC) and Crohn’s Disease (CD) have a major impact on quality of life and
medical costs. The aim of the study was to estimate the prevalence, incidence and clinical
phenotypes of Inflammatory Bowel Disease (IBD) cases in Mexico and Colombia.
Methods
We analyzed official administrative and health databases, used mathematical modelling to
estimate the incidence and complete prevalence, and performed a case-series of IBD
patients at a referral center both in Mexico and Colombia.
Results
The age-adjusted complete prevalence of UC per 100,000 inhabitants for 2015/2016 ranged
from 15.65 to 71.19 in Mexico and from 27.40 to 69.97 in Colombia depending on the model
considered. The prevalence of CD per 100,000 inhabitants in Mexico ranged from 15.45 to
18.08 and from 16.75 to 18.43 in Colombia.
In Mexico, the age-adjusted incidence of UC per 100,000 inhabitants per year ranged
from 0.90 to 2.30, and from 0.55 to 2.33 in Colombia. The incidence for CD in Mexico ranged
from 0.35 to 0.66 whereas in Colombia, the age-adjusted incidence of CD ranged from 0.30
to 0.57.
The case-series included 200 IBD patients from Mexico and 204 patients from Colombia.
The UC/CD prevalence ratio in Mexico and Colombia was 1.50:1 and 4.5:1 respectively. In
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Mexico, the female/male prevalence ratio for UC was 1.50:1 and 1.28:1 for CD, while in
Colombia this ratio was 0.68:1 for UC and 0.8:1 for CD. In Mexico the relapse rate for UC
was 63.3% and 72.5% for CD, while those rates in Colombia were 58.2% for UC and 58.3%
for CD.
Conclusions
The estimated burden of disease of IBD in Mexico and Colombia is not negligible. Although
these findings need to be confirmed by population-based studies, they are useful for deci-
sion-makers, practitioners and patients with this condition.
Introduction
Inflammatory bowel disease (IBD) is a term encompassing two main inflammatory diseases of
the colon and/ or small intestine: Crohn’s disease (CD) and Ulcerative Colitis (UC).[1] Diag-
nosis is based on clinical presentation, endoscopic findings and other imaging and histopatho-
logic findings. Both diseases are chronic and clinically intermittent with remissions and
relapses, possibly due to interactions between genetic and environmental factors.[2] Differen-
tiation between UC and CD is not always clear as symptoms overlap and extra-intestinal mani-
festations can be similar. Treatment of inflammatory bowel disease includes lifestyle changes
(e.g., smoking cessation for patients with CD), medical management, and surgical interven-
tions.[1]
IBDs have a major impact on life expectancy, quality of life and medical costs. For example,
patients with Crohn’s disease have a risk of dying over 50% higher than someone in the general
population of the same age.[3] IBD burden derives in an important increase of direct medical
costs, although this may vary across countries. A Canadian study showed that IBD doubles
healthy controls direct costs and that CD is on average 20% costlier than UC.[4]
Regarding UC, the cause of the disease is unknown; however, over-stimulation of an inade-
quately regulated mucosal immune system appears to be a major pathophysiological pathway.
The course of the disease is generally relapsing–remitting, with patients experiencing few or
no gastrointestinal symptoms in between symptomatic flare-ups (relapses).
The prevalence of UC in Europe and USA reaches 70–150 patients per 100,000 inhabitants.
[5] The overall mortality rates for CD have decreased around the world in the last twenty
years, but based on recently published nationwide data there is still excess mortality during the
disease course.[6,7] Mortality rates in CD vary in different regions of the world, that may be
related with different genetic, environmental, and health care related conditions.[6,7] IBD’s
epidemiology is well characterized in developed countries, but this is less so in Latin America
(LA). However, a study reports that since 1990 IBD incidence has been rising in newly indus-
trialized countries in South America and other regions[8]. A systematic review including LA
reported considerably lower prevalence rates for said region than for others[9] and marked
differences in the burden of the disease among countries. Environmental factors such as socio-
economic status, exposure to infections, use of antibiotics and issues of hygiene, might help
explain the epidemiological differences between populations.[10]
Some studies have attempted descriptions of the epidemiology of IBD in Latin America.
[11–18] UC incidences ranged from 0.74 to 6.76 per 100,000 inhabitants, 0.24 to 3.50 for CD,
and 0.42 to 2.46 for non-specified IBD. UC prevalence ranged from 0.99 to 44.3 per 100,000
inhabitants, 0.24 to 14.90 for CD and 0.42 to 38.22 for non-specified IBD.[18] Some case-series
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study design, data collection and analysis or
decision to publish.
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and descriptive studies also describe some features of these conditions in patients of LA. [19–
24]
Despite the little evidence from the IBD patients in Latin America, our hypothesis is that
the burden of disease in LA is not marginal. Considering this panorama of scarcity of epidemi-
ological, clinical and resource use information, we aimed at conducting a study to estimate the
prevalence, incidence and clinical phenotypes of IBD in Mexico and Colombia, two large
countries of the region for which data is also lacking.
Materials and methods
We performed a retrospective observational study following the Strengthening The Reporting
of Observational Studies in Epidemiology (STROBE) guidelines.[25] During 2018, we included
data from official administrative and health databases in Mexico and Colombia. We used the
tenth revision of the International Classification of Diseases (ICD 10) IBD, selecting codes
K50x (for CD) and K51x (for UC). We also explored related ICD codes, as K564: Other
obstructions of the intestine, K63 Other diseases of the intestines, K638 Other specified dis-
eases of the intestine, K639 Intestinal disease, unspecified, K591 Functional diarrhea, M075
Joint disease in ulcerative colitis, M095 Juvenile arthritis in ulcerative colitis and K529 Colitis
and gastroenteritis not infectious, not specified. However, we decided not to include these
additional codes because of their very low specificity. Because the capture-recapture approach
requires the inclusion of health facilities serving at least 80% of the population from a geo-
graphic area to estimate the target disease epidemiology with reasonable reliability, and this
type of centers does not exist in Mexico and Colombia, we had to resort to alternative methods.
We therefore analyzed official administrative databases, modelling incidence and prevalence
with mathematical models.
Mexico data
As part of the process of estimation of prevalence and incidence of IBD cases in Mexico, which
relate to the true burden of disease, we initially analyzed databases with information on hospi-
tal discharges by IBD, sex and age group generated by the Mexican public health sector.
Public sector discharge records were obtained from a standard-format database of hospital
discharges in the health sector (2009–2015), which is available on the website of the National
Health Information System (Sistema Nacional de Información en Salud—SINAIS) of the Gen-
eral Directorate of Health Information (Dirección General de Información en Salud—DGIS).
[26] This database includes more than 40 million hospital discharge records during the evalu-
ated period and provides basic information such as year of care, sex, age of patient, and main
condition. The records are coded according to the ICD-10,[27] length of stay, reason for dis-
charge, and hospital discharges from the care institution, and have been compiled by the Min-
istry of Health, the Mexican Social Security Institute (Instituto Mexicano del Seguro Social—
IMSS), Oportunidades IMSS, the Institute for Social Security and Services for State Workers
(Instituto de Seguridad Social y Servicios para Trabajadores del Estado—ISSSTE), PEMEX
and the Mexican Navy (SEMAR). According to the Official Mexican Standard, hospital dis-
charges information includes number of discharges due to cure, improvement, transfer to
another hospital unit, death or discharge, and excludes transfers between different services
within the hospital.[28] It is important to consider that while hospital discharge records com-
pile data for each event, a person can be admitted to the hospital on different occasions for the
same cause or for various reasons in the same period. In order to capture this phenomenon,
we used also the reported number of hospitalizations from the DGIS database.[26]
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For Mexico, the Population Council of Mexico (CONAPO) provided the population pro-
jections data for different calendar years.[29] The mortality data for the study period come
from the General Directorate of Health Information (DGIS).[30]
Colombia data
We obtained the number of patients with IBD as primary diagnosis from the Integral Informa-
tion System of Social Protection (SISPRO) database.[31] The SISPRO database, hosted by the
Colombian Ministry of Health and Social Protection, offers consolidated data coming from all
healthcare providers (hospitals and healthcare centers), which are obliged by law to report data
using the ICD-10 coding for the primary diagnosis, for all registered persons who demand ser-
vices within the Social Security Health System. It is considered that more than 90% of Colom-
bians are registered with SISPRO.
SISPRO does not provide information on IBD patients not reaching the healthcare system,
and thus there is no available data about them. To estimate the yearly incidence, we considered
a “new case” to be a person with a positive diagnosis not previously identified, who required
Health Services for the first time and is recorded as an IBD patient for the first time in SISPRO.
Official demographic information and vital statistics were obtained from the National Admin-
istrative Department of Statistics (DANE). [32]
Prevalence of persons with IBD contacting the health system out of the total registered pop-
ulation was used as a proxy of real prevalence. Incidence per 100.000 population-years was
based on the annual frequency of new IBD cases contacting the health system. These contacts
could be either emergency visits, ambulatory consultations and/or hospital discharges.
Modelling
We also used mathematical modelling to estimate the incidence and complete prevalence. Dis-
Mod II model is a multistate life table that simulates the epidemiological progress of a single
disease by exploiting the fact that parameters such as incidence, prevalence, remission, case
fatality and mortality rates are not independent variables.[33] Hence, it was designed to esti-
mate epidemiological parameters on diseases when the availability of measured data is scarce.
We used the Mexican and Colombian prevalence of the Institute of Health Metrics’ Global
Burden of Disease project, estimated with Disease Modeling Multiregression (DISMOD-MR)
as our input for the DISMOD II model for the years 2010 and 2016, for which data was avail-
able.[34],[35] We assumed zero remission rate.
We also ran MIAMOD, a model originally developed for cancer complete prevalence esti-
mates[36,37]. It uses a back-calculation method that could be applied to estimate the incidence
and complete prevalence of IBD, as a chronic condition, from specific age-gender mortality
and survival as inputs.[37] Mortality came from DGIS, and survival was extrapolated from
Danish IBD cases, being Denmark a country with extensive high-quality surveillance informa-
tion. Regarding the degree of coverage of mortality data we used WHO’s Global Health Obser-
vatory.[38] Mortality input values for models were adjusted for this type of under-reporting,
which was 5.5% for Mexico and 6% for Colombia, according to UN tables.[38] In order to esti-
mate complete prevalence figures with MIAMOD we performed a sensitivity analysis consid-
ering an additional correction of 10%, due to garbage coding, anticipating that this is the
model that provides the upper limit estimations.
Cases-series
Regarding clinical phenotypes of disease, during 2018 we chose two centers: Hospital Dr. Ber-
nardo Sepúlveda, Colorectal surgery Department, in Mexico City, Mexico; and Clı́nica
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Universitaria Colombia–EPS Sánitas in Bogotá, Colombia. Those centers collected retrospec-
tively a case-series of patients under clinical follow-up. These large referral centers included
both outpatients and inpatients, and the diagnosis of IBD was established according to the
most updated diagnostic recommendations for IBD. This included clinical features, endoscopy
of the colon, other biochemical and imaging procedures like video capsule or pan-endoscopy,
and biopsy. The date of IBD diagnosis was considered the starting point of the disease follow-
up, and the symptoms onset date was recorded separately. We gathered demographic data of
patients, family history of IBD, disease anatomical extension, severity of disease at the time of
diagnosis, signs and symptoms, hospitalization episodes, relapse dates, and treatment patterns.
We used a sample of 200 consecutive cases from the routine database of the clinic cases that
allow ±5% of semi-amplitude of the 95% confidence interval for the proportions of those least
frequent symptoms. Univariate statistical analyses were performed to outline the study popula-
tion. Wilcoxon test and X2 tests were done to determine differences in continuous and cate-
gorical variables, respectively. Dependent variable, UC clinical remission, was analyzed
according to the main variables collected, through a multivariable regression analysis. We pre-
sented central estimations with their 95% confidence Intervals (CI), both in tables and in
graphical format. We performed these analyses using Stata statistical software (v. 14.1, Stata-
Corp, College Station, TX).
The study was approved by the Ethics Committee of the Instituto Mexicano del Seguro
Social (IMSS), Ref. 09-B5-61-2800/201800 and by the Research Ethics Committee of the Fun-
dación Universitaria Sanitas, Bogotá Colombia, Act 017–18.
Results
Epidemiology in Mexico
Data from Mexican administrative databases allowed us to present discharge rates by IBD but
did not allow us to estimate incidence or prevalence of disease. In S1 and S2 Files, we present
the overall and by-age group rates per 100,000 population of hospital discharges by IBD type
and sex, and the discharge rates by age groups from 2010 to 2015 to complement our epidemi-
ological estimates based on SINAIS data.
We present the results using mathematical modelling (DISMOD II AND MIAMOD) to
estimate the incidence and complete prevalence.
The age-adjusted complete prevalence of UC per 100,000 inhabitants for 2015/2016 ranged
from 15.65 to 71.19, depending on the model considered. The prevalence of CD per 100,000
inhabitants, ranged from 15.45 to 18.08. The age-adjusted incidence of UC per 100,000 inhabi-
tants per year, ranged from 0.90 to 2.30, and for CD ranged from 0.35 to 0.66 using both mod-
els. The prevalence by sex for 2010 and 2015/2016 is presented in Table 1.
The MIAMOD adjusted prevalence was twice as high as the DisMod II for men and six
times the value for females, and regarding CD they were quite similar.
The MIAMOD adjusted was 1.5 and three times higher than the DisMod II in male and
female UC incidence, respectively. We found similar female CD incidence and around two
times higher for males (Table 1).
The female-male ratio for UC prevalence was 2.1: 1 and for the CD prevalence was 0.8:1
(MIAMOD) and 0.7:1 and 1:1 using DisMod II.
Epidemiology in Colombia
We collected information of the years 2010–2015 from SISPRO, the most complete from the
database inception. We found a total of 51,330 people who consulted with the Colombian
Health System between 2010 and 2015. These people visited different centers whose data are
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submitted to the SISPRO registry. Table 2 shows the information from this database, present-
ing the yearly number of people who have been admitted to hospitals, who have used the emer-
gency services and who have received medical procedures due to inflammatory bowel disease
at the outpatient setting.
The frequency of drugs prescriptions in patients with IBD came from a sub-database of SIS-
PRO including 837 patients who received specific IBD medication during the period 2010 to
2015. There was no data available for the calendar year 2012. About 72% (n = 599) received
azathioprine while 56% (n = 469) and 36% (n = 305) received mesalazine and steroids,
respectively.
According to our results, in Colombia the age-adjusted complete prevalence of UC per
100,000 inhabitants for 2015/2016 ranged from 27.40 to 69.97 depending on the model consid-
ered. The prevalence of CD per 100,000 inhabitants, ranged from 16.75 to 18.43. The age-
adjusted incidence of UC per 100,000 inhabitants per year, ranged from 0.55 to 2.33, and for
CD ranged from 0.30 to 0.57, respectively. These estimations were very similar to the 2010 esti-
mations. The separate estimations by gender are presented in Table 3. The MIAMOD adjusted
complete prevalence was 2 to 3 times higher than the DisMod II prevalence for UC and from
0.7 to 1.4 for CD. The MIAMOD adjusted incidence was 2 to 3 times higher than the DisMod
Table 1. Mexico 2010–16. Comparison of complete population prevalence and incidence rates of total IBD, as modelled by DisMod II and MIAMOD for the years 2010
and 2015/16.
Outcomes Years Ulcerative Colitis Crohn’s Disease
Male Female Male Female
DisMod II† MIAMOD DisMod II†† MIAMOD DisMod II# MIAMOD DisMod II## MIAMOD
Base +10%� Base +10%� Base +10%� Base +10%�
Prevalence 2010 19.20 39.80 43.90 17.79 84.08 98.30 21.16 18.15 20.02 16.71 14.63 16.09
2015/16 17.00 39.84 43.95 14.3 84.20 98.43 20.50 18.16 20.05 10.40 14.65 16.11
Incidence 2010 1.00 1.41 1.55 0.68 2.65 3.05 0.30 0.68 0.75 0.30 0.52 0.57
2015/16 1.00 1.41 1.55 0.80 2.65 3.05 0.30 0.68 0.75 0.40 0.52 0.57
Prevalence inputs based on DISMOD-MR [34],[35]
†22 (2010) and 21 (2016)
††16 (2010) and 15 (2016)
#13 (2010) and 12 (2016)
##10 (2010) and 8.4 (2016).
�Results from MIAMOD with an adjusted of 10% in the specific mortality data; NE: Not Estimated.
https://doi.org/10.1371/journal.pone.0228256.t001
Table 2. Colombia 2010–15. Number of hospital discharges, emergency and outpatient visits, by IBD type and sex (all ages).
Year Ulcerative Colitis Crohn’s Disease
Males Females Males Females
Hospital Emerg. Outp. Hospital Emerg. Outp. Hospital Emerg. Outp. Hospital Emerg. Outp.
2010 137 129 3003 181 185 4166 20 25 487 10 23 801
2011 182 201 3639 252 266 4858 30 43 527 25 39 736
2012 211 280 4013 248 364 5355 39 53 526 38 65 643
2013 189 326 4190 217 395 5614 32 48 520 21 56 733
2014 224 385 4655 254 535 6291 43 58 603 32 67 796
2015 211 253 4124 268 342 5689 45 34 501 37 49 643
Source: SISPRO database
https://doi.org/10.1371/journal.pone.0228256.t002
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II incidence for UC (although seven times higher for females) and from 1.6 to 2.3 times higher
for CD. Regarding the comparison with SISPRO, the MIAMOD adjusted prevalence was 3 to
4 times higher than the cumulative proportion of UC patients registered in SISPRO, and 5 to 7
times higher for patients affected of CD.
In the S2 File we show the prevalence of IBD by sex and age group estimated using the
MIAMOD model base case for both countries. The S1 File show the Colombian prevalence of
UC and CD among health system users by age group from 2010 to 2015.
Case-series
We recruited 404 IBD patients from Mexico D.F and Bogota City. The case-series in Mexico
included a total of 200 patients with a diagnosis of IBD, 120 individuals had UC (60%) and 80
patients had CD (40%). The UC/CD ratio was 1.5: 1. The female-male ratio in UC was 1.5: 1
(60% vs 40%), and the CD ratio was 1.28: 1 (56.25% vs 47.75%). The Colombian case-series
included a total of 204 patients with a diagnosis of IBD, 165 individuals had UC (80.88%), 36
patients had CD (17.65%) and 3 patients had an unclassifiable type of IBD (1.47%). The UC/
CD ratio was 4.5:1. The female/male ratio in UC was 0.68:1 (40.61% vs 59.4%), and 0.8:1
(44.44% vs 55.56%) for CD. See Table 4.
Table 5 shows the most frequent clinical manifestations in IBD patients in both countries.
The most frequent symptoms in both case-series were diarrhea, rectal bleeding and abdominal
pain. Table 6 shows the prevalence ratio of the clinical manifestations in IBD patients of both
cases-series. In Mexico, anorexia and weight loss were the clinical features most significantly
related with UC, while abdominal pain was the symptom most frequently associated with CD.
In relation with Colombian patients, bleeding was the clinical feature most significantly related
with UC, while weight loss, abdominal pain, bowel obstruction and arthritis were the signs/
symptoms most associated with CD. Diarrhea is equally prevalent in both pathologies.
Among Mexican patients, the most frequent anatomical involvement in CD patients were
ileocolonic (37%) and colonic (30%) while the most frequent anatomical localization of UC
patients was pancolitis with 55.83%, while left-sided colitis and proctitis were 34.17% and 10%,
respectively. In Colombia, the most frequent anatomical involvement in CD patients were
ileo-terminal (55%) and ileocolonic (39%), while the most frequent anatomical localization of
UC patients was pancolitis with 39%, left-sided colitis 33.5% and proctitis 27.5%.
Table 3. Comparison of complete population prevalence and incidence rates of UC and CD as modelled by DisMod II and MIAMOD for Colombia in the years
2010 and 2015/6, and from SISPRO.
Outcomes Years Ulcerative Colitis Crohn’s Disease
Male Female Male Female
SISPRO DisMod II† MIAMOD SISPRO DisMod II†† MIAMOD SISPRO DisMod II# MIAMOD SISPRO DisMod II## MIAMOD
Base +10%� Base +10%� Base +10%� Base +10%�
Prevalence 2010 16.76 16.57 47.79 52.36 21.8 19.24 79.27 87.2 2.73 19.29 12.89 14.17 4 15.38 20.58 22.64
2015/6 20.25 26.6 47.85 54.3 26.72 28.2 79.39 87.33 2.56 20.2 12.9 14.19 3.1 16.6 20.61 22.68
Incidence 2010 13.7 0.81 1.69 1.86 18.4 0.48 2.52 2.81 2.6 0.31 0.44 0.48 3.9 0.29 0.61 0.7
2015/6 13.5 0.7 1.69 1.86 18.8 0.4 2.48 2.81 1.6 0.3 0.43 0.48 2.1 0.3 0.60 0.7
Prevalence inputs based on DISMOD-MR34,35
†19 (2010) and 19 (2016)
††15 (2010) and 14 (2016)
#12 (2010) and 12 (2016)
##9.7 (2010) and 8.7 (2016).
�Results from MIAMOD with an adjusted of 10% in the specific mortality data; NE: Not Estimated.
https://doi.org/10.1371/journal.pone.0228256.t003
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At time of data collection, the most frequent clinical condition in Mexican UC patients was
clinical remission (83%), followed by mild and moderate compromise (14% and 3% respec-
tively). Out of 102 of patients in remission, 100 presented clinical remission, 68 biochemical
remissions, 63 presented endoscopic remission and 28 patients presented histopathological
remission. In Colombia, 58% of UC patients presented clinical remission, 26% being mild, and
16% moderate in the category of severity.
In the Mexican case-series, the relapse rate of the IBD patients was 67% (134/200). The UC
relapse rate was 63.33% (n = 76), while the CD relapse rate was 72.5% (n = 58) without statis-
tics difference (p = 0.15). In comparison, in the Colombian case-series the relapse rate for IBD
was 57.4% (117/204); 58.2% in UC patients (96/165), and 58.3% in CD ones (21/36).
Table 4. Clinical characteristics of UC and CD patients in the case-series of patients in Mexico City (n = 200) and


















Women n (%) 72 (60) 45 (56.25) 0.59� 67 (40.6) 16 (44.4) 2 (66.7) 0.62�
Ever smoker (%) 50 (41.6) 42 (52.5) 0.44� 35 (21) 8 (22) - 0.55�
Age at diagnosis—
median (min-max)
40 (28.5–49.5) 49.5 (30.5–
61.5)
0.03# 38 (12–80) 49 (12–85) 51 (25–68) 0.14#
Symptoms starting age
—median (min-max)




0 (0–1) 0.5 (0–2) 0.1# 0 (0–11) 0.5 (0–2) - 0.39#
� X2 tests
# Test U of Mann-Whitney.
https://doi.org/10.1371/journal.pone.0228256.t004
Table 5. Clinical signs and symptoms observed in IBD case-series of patients in both countries.












Diarrhea n(%) 118 (98.50) 72 (90.00) 0.01 151 (91.5) 31 (86.1) 0.85
Rectal bleeding n(%) 119 (99.20) 72 (90.00) 0.01 147 (89.1) 24 (67.7) 0.01
Abdominal Pain n
(%)
92 (77.00) 32 (40.00) 0.06 127 (77) 32 (88.9) 0.1
Weight Loss n(%) 43 (35.83) 52 (65.00) <0.01 79 (47.9) 23 (63.9) 0.08
Bowel obstruction n
(%)
17 (14.16) 19 (23.75) 0.07 11 (6.7) 5 (13.9) 0.05
Anorexia n(%) 24 (20.00) 39 (48.75) <0.01 42 (25.4) 13 (36.1) 0.04
Fatigue n(%) 37 (30.83) 45 (56.25) <0.01 8 (4.8) 4 (11.1) 0.23
Others symptoms n
(%)
2 (1.74) 11 (13.75) 0.01 6 (3.6) 0 0.5
Arthritis/arthralgias
n(%)
66 (55.00) 45 (56.25) 0.76 9 (5.4) 5 (13.9) 0.05
� X2 tests
https://doi.org/10.1371/journal.pone.0228256.t005
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In the UC group, 27.63% (21/76) of the Mexican patients presented the relapse between the
first five years after diagnosis and the same number of patients relapsed after five years (21/76).
Regarding the CD patients who presented relapses, 31.03% (18/58) and 22.41% (13/58)
relapsed during the first five years and after the fifth year from diagnosis, respectively.
In Colombia, for those 96 UC patients who relapsed, 23% did so during the first 12 months
after diagnosis, 53% between one year and five years after diagnosis, and 22% after five years,
with 2% of patients with missing information. For those 21 CD patients who relapsed, 24% did
in the first 12 months after diagnosis, 62% within the first to fifth year and the remaining 14%,
after 5 years to diagnosis.
In Mexican case-series, 38% of UC cases (n = 46) and 72.5% of CD ones (n = 59) required
hospitalization. The median number of hospitalizations in patients with UC was 1 (min-max:
1–4) and 2 (min-max: 1–15) in CD patients. The percentage of UC patients who required sur-
gery during the follow-up was 10% (n = 12), contrasting with CD patients, who needed a sur-
gery in 58.75% (n = 47) of cases.
If we consider the Colombian case series, 27% of UC cases (n = 45) and 36% of CD ones
(n = 13) required hospitalization. The median number of hospitalizations in patients with
ulcerative colitis was 1 (min-max: 1–8) while the median number of hospitalizations in
patients with CD was 2 (min-max: 1–11). The percentage of UC patients who required surgery
during the follow-up was 2% (n = 3), contrasting with CD patients, who needed surgery in
28% (n = 10) of cases.
Regarding the treatment pattern distribution, in Mexican UC case-series, 5-aminosalicylic
acid (5-ASA) was the most frequent choice (98%), followed by steroids (48%), azathioprine
(47%) and biologicals (22%); and among the CD patients, the most frequent were 5-ASA
(98%), azathioprine (76%), biologicals (76%) and steroids (64%). In Colombia, 97% of UC
patients received 5-ASA, and 56%, 51% and 20% used steroids, azathioprine and biological
drugs, at any time during follow-up, respectively. For CD patients, the most frequent were ste-
roids (86%), followed by azathioprine (84%), biologicals (64%) and finally 5-ASA (39%).
Table 6. Prevalence ratio of selected clinical manifestations in UC versus CD patients, by country (2018).
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Variable Prevalence ratio UC� vs
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Discussion
This work presented novel estimates of IBD disease burden and clinical features of affected
patients in two Latin American countries, Mexico and Colombia. Given the lack of informa-
tion on nationwide prevalence and incidence of IBD, we estimated them through different
mathematical models and provided supplementary information coming from large official
health system databases. To our knowledge, this is the first study doing so in both countries. In
the case of Mexico, the official health system databases do not report persons with hospitaliza-
tions related to IBD. In Colombia, on the other hand, the cumulative proportion of IBD
patients registered in SISPRO represents a good approximation of the country prevalence con-
sidering that most cases require the health system intervention and that the database is
updated annually.
When we first analyzed the SISPRO incidence, we expected the biggest incidence rate to be
for 2010, but we obtained similar values for incidence over the years that we included in the
analysis. We consider two situations that may impact on the number of cases that have been
registered in SISPRO: 1) the uploading of the cases depends on whether the administrative
employees and physicians do that; and 2) the coverage of SISPRO has been growing in the last
years and it is possible that each year different health centers are incorporated to the registry.
For Mexico, our study estimated a UC prevalence of 71 per 100,000 inhabitants (44 for
males and up to 98 for females) in 2015/16; and of 18 for CD, (20 for males and up to 16 for
females). The UC incidence per 100,000 inhabitants was 2.30 (1.55 for males and up to 3.05 for
females), and for CD, it was 0.66 (0.75 and up to 0.57 for males and females respectively).
For Colombia, the UC prevalence was 70.5 per 100,000 inhabitants (54 for males and up to
87 for females in 2015/6); and for CD it was 21.5 per 100,000 inhabitants (20 for males and up
to 23 for females). The UC incidence per 100,000 inhabitants was 2.3 per 100,000 inhabitants
(1.86 for males and up to 2.81 for females), and for CD it was 0.59 per 100,000 inhabitants
(0.48 for males and up to 0.7 for females).
The IBD prevalence figures obtained with MIAMOD for Mexico and Colombia were higher
than those reported in a previous systematic review carried out by our research team in Latin
American countries, in which the prevalence for UC ranged from 0.99 to 44.3 per 100,000
inhabitants, and from 0.24 to 14.90 for CD.[18]
IBD epidemiology has been studied in developed countries in a more comprehensive way,
as noted by Ng et al in a study showing a rising incidence in industrialized countries in Africa,
Asia, and South America since 1990.[8] The highest reported prevalence rates for IBD were in
Europe (UC, 505 per 100,000 persons; CD, 322 per 100,000 persons) and in North America
(UC, 286 per 100,000 persons in USA; CD, 319 per 100,000 persons in Canada).[9,10] Differ-
ences between countries could be explained by several factors, including migration rates,
genetic profiles, environment or socioeconomic factors, and also by methodological limita-
tions of epidemiologic studies, including design or diagnostic approach, differences in popula-
tion characteristics, and access to health care.[39],[40] Of note, all of those prevalence and
incidence rates are much higher than those coming from a few well-conducted Latin American
population-based studies.[18]
A study has revealed a decreasing geographical North-South gradient for IBD incidence.
One possible explanation would be that in northern regions, there is low exposure to sunlight,
as well as vitamin D plasma levels.[41] However, its causal relationship with IBD is still uncer-
tain. The lower IBD prevalence in Mexico and Colombia compared to other countries in
North America could also be due to their latitude, but considering the absence of population-
based prevalence studies this theory deserves further research.
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The varying range of our estimations can be partly explained by structural differences
between models. DisMod II is a state-transition model which requires the population struc-
ture, general and specific mortality, remission and prevalence as input.[33] On the other hand,
MIAMOD is a model of multiple and polynomial regressions that uses all-cause mortality, spe-
cific mortality, relative survival and population structure as input. As stated, MIAMOD model
is a method primarily developed for cancers with long survival, to be used in countries with a
sound surveillance system capable of adequately capturing survival rates. It has been used for
colon and breast cancer and could potentially be applied to other chronic conditions like IBD.
[36,37] Also as there might be some concerns regarding the quality of the survival data used
for feeding MIAMOD, we decided to use the 14-year Denmark’s nationwide cohort, as the
best available surrogate input of the age-adjusted survival.[42] Although it can be argued that
IBD patients survival in a low- and middle-income country could be lower than in a high-
income country, the magnitude of the difference would be minor since IBD mortality is low.
[18] In general, MIAMOD prevalence and incidence estimates were higher than DisMod II
model estimations.
The DisMod II model estimations and SISPRO information were quite similar regarding
prevalence. Yepes Barreto et al in 2010 published a small case-series of adult population from a
social security institution in Cartagena, and estimated an overall IBD prevalence in their popu-
lation of 29 per 100,000 (95%CI 17–40), which is in the range of our estimations.[43]
Additionally, another source reinforced our estimations for prevalence. In 2016, the Health
Metrics and Evaluation (IHME) published the updated Global Burden of Disease (GBD) for
prevalence and incidence in Mexico and Colombia, in which they used the DisMod-MR
model. This model is based on Bayesian meta-regression and uses an extensive temporal series
of population surveys as input.[34],[35] For Mexico, the GBD study estimated a 2016 UC prev-
alence per 100,000 inhabitants of 22 for males and 16 for females. For CD, it estimated a preva-
lence per 100,000 inhabitants of 12 and 9 for males and females, respectively. For Colombia,
the GBD study estimated a 2016 UC prevalence per 100,000 inhabitants of 22 for males and 17
for females. For CD, it estimated a prevalence per 100,000 inhabitants of 12 and 9.4 for males
and females, respectively. However, we identified some inconsistencies in the GBD reported
incidence data for both countries, like the finding of higher incidence than prevalence rates.
We also analyzed the UC and CD GBD prevalence compared with the best quality popula-
tion-based nationwide studies.[8] With the exception of two cases with just a one-digit preva-
lence (Romania and Taiwan), in all cases (Hungary, Japan, Barbados, Sweden, Germany,
Denmark, Canada, Norway and Finland) GBD largely under-estimated the real prevalence.
For this reason, we consider that our DisMod II estimations are conservative and the real prev-
alence could probably be higher and closer to our MIAMOD-derived estimations.
Our study had several limitations related mainly to the quality of available data and many
assumptions required modelling the IBD incidence and prevalence by these novel methods.
For example, the exercise of MIAMOD outside the field of oncology, with information only
for a relatively small number of years and using foreign survival data, may threaten the validity
of its estimates. Additionally, since the relative survival rates were not available, we used the
observed absolute survival rates that could result in underestimation of the real prevalence
rates.
On the other hand, the multiple methodological and epidemiological verification sources
used to increase the confidence in our estimations represent a clear strength of our study. In
Colombia, SISPRO databases also provided further valuable information like the number of
hospital discharges, emergency and outpatient visits and treatment pattern by IBD type and by
sex for all ages. A limitation of this database is that if a patient does not contact the health sys-
tem, then that IBD case is ignored.
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We found similar results in other case-series in Mexico and Colombia but with some differ-
ences. [44–47]
A recent multicentric nationwide study evaluated the clinical and socio-demographical
characteristics of 2645 Mexican IBD patients from February to October 2017, with results that
are consistent with our case-series.
Regarding the description of clinical phenotypes of Colombian IBD cases, Baños et al also
reported a case-series of 202 patients drawn from a convenience sample in Medellı́n, Colom-
bia. IBD patients (CD 15.8%, UC 80.7%) who consulted the reference center Hospital Pablo
Tobón Uribe between August 2001 and July 2009 were systematically evaluated.[46] A slight
predominance in the female group (56.4%) and an average age of onset of 37 years of age was
found. The percentage of patients with extra-intestinal involvement was 27.7% and the time of
diagnosis from the onset of symptoms was 9.2 months for UC and 13.2 for CD. The 35% of
patients affected with UC presented extensive colitis and only 23.1% of them showed severe
symptoms. The anatomical compromise of the patients with CD was predominantly ileocolo-
nic (50%) and the inflammatory, stenotic and perianal behavior was of similar proportions in
this group. The proportion of patients with UC who were in clinical remission was higher than
that published by Baños (58.7% vs 17.2%) while the proportion of patients with mild UC was
similar for both series of cases, probably due to newer available treatments.[46] Consistently,
the proportion of patients with UC who had been hospitalized was 30.4% and 58.1% for CD
while the value for the other case -series was 42.9% and 75% respectively.[46] Biological ther-
apy was used in 7.4% of patients with UC and in 47% of patients with CD and its use was
related to the risk of requiring surgical treatment in the two diseases.[48]
A previous large case-series of 848 patients with UC in Mexico reported by Yamamoto-Fur-
usho in 2009[20] showed that the largest proportion of patients diagnosed with this pathology
is between 21 and 30 years of age. The mean age at diagnosis was 31.3 years, while the median
age was 38 years for patients with UC, lower than the ones in our study. The main clinical
manifestations such as diarrhea, bleeding and abdominal pain were consistent with our case-
series, as was the percentage of patients who required surgery (10%).[20] In relation with the
distribution of the extent of the UC, it was consistent with our study. The comparative treat-
ment pattern varied between our more recent series and the Yamamoto series: 5 ASA (98 vs.
64%), steroids (48 vs. 33%), azathioprine (47 vs 28%) and biologicals (22 vs 1%), respectively.
[20] Another small case-series presented similar clinical manifestations and surgery require-
ments but different treatment patterns: 5 ASA (100%), steroids (7%), and biologicals (7%).[24]
Other case-series of 104 patients with IBD showed that out of the 75 patients with UC, 55%
had mild disease, 30% moderate disease and 15% severe disease.[23] Another study by Yama-
moto-Furusho et al found that elderly patients with CD had a mild clinical course character-
ized by long-term remission and no escalation to immunosuppressive and anti-tumor necrosis
factor therapy.[49]
Of interest, a cohort analysis of 184 cases in Mexico found that pancolitis, hypoalbumine-
mia and previous hospitalizations were the strongest predictors of procto-colectomy.[50]One
study found a higher prevalence of left-sided colitis, higher mortality, and higher usage of bio-
logical agents in Mexican population than in Mexican-American population, supporting the
role of environmental factors on clinical characteristics of IBD.[24]
The larger case-series in LAC Countries are from 1946 to date are from Argentina
[14,51,52], Barbados[13], Brazil[14,53–65], Chile[66–68], Cuba[69], Peru[70,71], Puerto Rico
[72–75] and Uruguay.[76–78] Most CD localizations were ileal-colonic and CD behavior was
mostly inflammatory, followed by penetrant or stenotic. Perianal disease was identified
roughly in one out of four cases. Regarding UC extension, it varied a lot, but extensive colitis
was the most prevalent in these cases series, followed by left-sided and proctitis.
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Conclusion
Despite the aforementioned difficulties in approaching real IBD estimations in a scenario of
paucity of representative data, we showed that the burden of IBD in Mexico and Colombia
should not be considered negligible. Moreover, given the high variability observed in the
reporting of IBD epidemiology worldwide, depicting real-world burden of these conditions
remains to be a global challenge.
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enterol Mex. 73: 38–42. Available: internal-pdf://0525892513/Sandoval2008.pdf
23. Bosques-Padilla FJ, Sandoval GER, Martı́nez-Vazquez MA, Garza E. G, Maldonado-Garza HJ. Epide-
miology and clinical characteristics of ulcerative colitis in north-eastern Mexico. Rev Gastroenterol Mex.
2011; 34–38. Available: internal-pdf://232.138.161.93/BosquesPadilla2011.pdf PMID: 21592901
24. De la Cruz-Guillén AA, Cortés-Espinosa T, Sánchez-Chávez X, López Gómez JG, Quintero Aguilar G,
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Clinical and sociodemographical characteristics of inflammatory bowel disease in Mexico: Multicentric
Epidemiology of inflammatory bowel disease in Mexico and Colombia
PLOS ONE | https://doi.org/10.1371/journal.pone.0228256 January 27, 2020 15 / 17
nation-wide study (EPIMEX- IBD). Am J Gastro. 2018; 113: p-044. Available: https://journals.lww.com/
ajg/Citation/2018/02001/Clinical_and_Sociodemographic_Characteristics_of.44.aspx
45. Paredes-Méndez J, Otoya-Moreno G, Mestanza-Rivas-Plata AL, Lazo-Molina L, Acuña-Ordoñez K,
Arenas-Gamio JL, et al. Caracterı́sticas epidemiológicas y clı́nicas de la enfermedad inflamatoria intes-
tinal en un hospital de referencia de Lima-Perú. Rev Gastroenterol del Perú. 2016; 36: 209–218.
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